Cyclacel receives Nasdaq bid-price deficiency notice; stock at risk of delisting

Bio Green Med Solution, Inc.

Nasdaq notified Cyclacel on Dec 6, 2024, that common stock bid price below $1.00 for 30 consecutive business days.
Company has 180 calendar days (until June 4, 2025) to regain compliance by closing at $1.00+ for 10 consecutive days.
If not compliant by June 4, 2025, Nasdaq may delist common stock; company may appeal to hearings panel.
Cyclacel is considering alternatives including a potential reverse stock split to meet the bid-price rule.
Common stock continues trading on Nasdaq under symbol CYCC during the grace period.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.